[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EE200300166A - 7-Azaindoles, process for their synthesis, their use in the manufacture of medicaments for the inhibition of TNFα or phosphodiesterase-4, and medicaments containing them - Google Patents

7-Azaindoles, process for their synthesis, their use in the manufacture of medicaments for the inhibition of TNFα or phosphodiesterase-4, and medicaments containing them

Info

Publication number
EE200300166A
EE200300166A EEP200300166A EEP200300166A EE200300166A EE 200300166 A EE200300166 A EE 200300166A EE P200300166 A EEP200300166 A EE P200300166A EE P200300166 A EEP200300166 A EE P200300166A EE 200300166 A EE200300166 A EE 200300166A
Authority
EE
Estonia
Prior art keywords
medicaments
azaindoles
tnfα
phosphodiesterase
inhibition
Prior art date
Application number
EEP200300166A
Other languages
Estonian (et)
Inventor
H�Fgen Norbert
Egerland Ute
Kronbach Thomas
Marx Degenhard
Szelenyi Stefan
Kuss Hildegard
Polymeropoulos Emmanuel
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10053275A external-priority patent/DE10053275A1/en
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of EE200300166A publication Critical patent/EE200300166A/en
Publication of EE05271B1 publication Critical patent/EE05271B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
EEP200300166A 2000-10-27 2001-10-25 7-Azaindoles, process for their synthesis, their use in the preparation of drugs inhibiting TNFα or phosphodiesterase-4, and drugs containing them EE05271B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10053275A DE10053275A1 (en) 2000-10-27 2000-10-27 New 7-aza-indole-3-carboxamides or glyoxylamides, useful e.g. for treating rheumatoid arthritis, osteoporosis, sepsis, asthma or multiple sclerosis are phosphodiesterase-4 and tumor necrosis factor-alpha inhibitors
US24434200P 2000-10-30 2000-10-30
PCT/EP2001/012376 WO2002034747A1 (en) 2000-10-27 2001-10-25 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same

Publications (2)

Publication Number Publication Date
EE200300166A true EE200300166A (en) 2003-08-15
EE05271B1 EE05271B1 (en) 2010-02-15

Family

ID=26007507

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300166A EE05271B1 (en) 2000-10-27 2001-10-25 7-Azaindoles, process for their synthesis, their use in the preparation of drugs inhibiting TNFα or phosphodiesterase-4, and drugs containing them

Country Status (28)

Country Link
US (3) US7169787B2 (en)
EP (1) EP1330455B1 (en)
JP (1) JP4233322B2 (en)
KR (2) KR100880586B1 (en)
CN (1) CN1247576C (en)
AR (1) AR034269A1 (en)
AT (1) ATE301121T1 (en)
AU (2) AU2175302A (en)
BG (1) BG66169B1 (en)
BR (1) BR0114903A (en)
CA (1) CA2428468C (en)
CZ (1) CZ20031146A3 (en)
DE (1) DE50106993D1 (en)
DK (1) DK1330455T3 (en)
EE (1) EE05271B1 (en)
ES (1) ES2246349T3 (en)
HK (1) HK1053839A1 (en)
HR (1) HRP20030427B1 (en)
HU (1) HUP0303034A3 (en)
IL (2) IL155386A0 (en)
MX (1) MXPA03003624A (en)
NO (1) NO324947B1 (en)
NZ (1) NZ525369A (en)
PL (1) PL213999B1 (en)
PT (1) PT1330455E (en)
SK (1) SK287774B6 (en)
TW (1) TWI262920B (en)
WO (1) WO2002034747A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
MXPA05004780A (en) * 2002-11-06 2005-10-05 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases.
DE10318610A1 (en) * 2003-04-24 2004-11-11 Elbion Ag 7-azaindoles and their use as therapeutic agents
US20050054691A1 (en) * 2003-08-29 2005-03-10 St. Jude Children's Research Hospital Carboxylesterase inhibitors
US7749999B2 (en) * 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
US7585859B2 (en) 2004-05-06 2009-09-08 Plexxikon, Inc. PDE4B inhibitors and uses therefor
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
EP1786813A2 (en) * 2004-09-03 2007-05-23 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
CN101355876B (en) 2005-11-09 2012-09-05 康宾纳特克斯公司 Compositions for the eye adminstration
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
CA2651732C (en) 2006-05-18 2014-10-14 Mannkind Corporation Intracellular kinase inhibitors
US20100056791A1 (en) * 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
US8012992B2 (en) * 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
WO2010033981A2 (en) * 2008-09-22 2010-03-25 Isis Innovation Ltd. 5-azaindole bisphosphonates
AU2010288553A1 (en) * 2009-08-26 2012-04-12 Takeda Gmbh Methylpyrrolopyridinecarboxamides
WO2012072727A1 (en) * 2010-12-03 2012-06-07 Biotie Therapies Gmbh Crystalline modification of n-(3,5-dichloropyridin-4-yl)-[1-(4 -fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide as inhibitor of pde4
WO2012080329A1 (en) 2010-12-17 2012-06-21 Biotie Therapies Gmbh Formulations of n-(3,5-dichloropyridin-4-yl)-[1-(4-fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide
CN102584842A (en) * 2011-01-17 2012-07-18 北京大学 Preparation of substituted indole lactam derivative and application of substituted indole lactam derivative as antimalarial agent
CN104736202B (en) 2012-08-22 2021-09-07 康奈尔大学 Methods for inhibiting fascin
DK3107902T3 (en) * 2014-02-20 2021-05-03 Cornell Univ Cornell Center For Technology Enterprise & Commercialization Cctec CONNECTIONS AND METHODS OF INHIBITING FASCIN
EP3863638B1 (en) * 2018-10-12 2024-06-26 Board of Regents of the University of Nebraska Phosphodiesterase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
WO1991009598A1 (en) 1990-01-05 1991-07-11 Pfizer Inc. Azaoxindole derivatives
US5023265A (en) 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5811432A (en) 1990-11-09 1998-09-22 Pfizer Inc Azaoxindole derivatives
DK0652868T3 (en) 1992-07-28 2005-02-14 Aventis Pharma Ltd Inhibitors of c-AMP phosphodiesterase
HUT71553A (en) 1992-08-06 1995-12-28 Warner Lambert Co 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
JP3119758B2 (en) * 1993-02-24 2000-12-25 日清製粉株式会社 7-Azaindole derivative and antiulcer drug containing the same as active ingredient
PT758233E (en) 1994-04-21 2004-04-30 Schering Ag PDE IV INHIBITORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
GB9420521D0 (en) * 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
JPH09169665A (en) 1995-12-21 1997-06-30 Kenichi Miyamoto Agent for treatment osteoporosis
JP3601898B2 (en) 1996-02-14 2004-12-15 俊隆 鍋島 Drug-dependent formation inhibitor
AUPO282996A0 (en) * 1996-10-07 1996-10-31 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
AU3868500A (en) * 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
SK287774B6 (en) 2011-09-05
CN1484644A (en) 2004-03-24
US20040106641A1 (en) 2004-06-03
CA2428468A1 (en) 2002-05-02
HRP20030427B1 (en) 2006-04-30
PL213999B1 (en) 2013-06-28
CN1247576C (en) 2006-03-29
US7169787B2 (en) 2007-01-30
MXPA03003624A (en) 2004-12-02
ATE301121T1 (en) 2005-08-15
CZ20031146A3 (en) 2003-10-15
US7419987B2 (en) 2008-09-02
CA2428468C (en) 2011-06-14
HRP20030427A2 (en) 2003-08-31
EP1330455B1 (en) 2005-08-03
NO20031722D0 (en) 2003-04-14
KR100837099B1 (en) 2008-06-13
HUP0303034A3 (en) 2012-12-28
PT1330455E (en) 2005-10-31
HK1053839A1 (en) 2003-11-07
TWI262920B (en) 2006-10-01
IL155386A (en) 2008-06-05
HUP0303034A2 (en) 2003-12-29
SK5092003A3 (en) 2004-08-03
EP1330455A1 (en) 2003-07-30
DE50106993D1 (en) 2005-09-08
JP2004512337A (en) 2004-04-22
AR034269A1 (en) 2004-02-18
JP4233322B2 (en) 2009-03-04
BG66169B1 (en) 2011-10-31
US20080207680A1 (en) 2008-08-28
NO20031722L (en) 2003-04-14
DK1330455T3 (en) 2005-12-05
IL155386A0 (en) 2003-11-23
US7683074B2 (en) 2010-03-23
NZ525369A (en) 2004-09-24
WO2002034747A1 (en) 2002-05-02
EE05271B1 (en) 2010-02-15
BG107725A (en) 2004-08-31
PL362837A1 (en) 2004-11-02
BR0114903A (en) 2003-10-14
US20060258700A1 (en) 2006-11-16
KR20080016758A (en) 2008-02-21
NO324947B1 (en) 2008-01-07
ES2246349T3 (en) 2006-02-16
AU2175302A (en) 2002-05-06
AU2002221753B2 (en) 2006-12-14
KR100880586B1 (en) 2009-01-30
KR20030065499A (en) 2003-08-06

Similar Documents

Publication Publication Date Title
EE200300166A (en) 7-Azaindoles, process for their synthesis, their use in the manufacture of medicaments for the inhibition of TNFα or phosphodiesterase-4, and medicaments containing them
EE200400059A (en) Diarylcycloalkyl derivatives, their use in the manufacture of medicaments, and medicaments containing them
HUP0400784A3 (en) Bicyclic heterocondensated pyrrolcarboxamide derivatives, their use and pharmaceutical compositions containing them
EE05149B1 (en) Biar acarboxamides, process for their preparation, pharmaceutical composition containing them and their use in therapy
EE05001B1 (en) Heterocyclic compounds, process for their preparation, pharmaceutical composition containing them and their use in therapy
NO20021382D0 (en) Methods and microorganisms for the preparation of panto compounds
HUP0300819A3 (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
PT1296974E (en) 2-cyanopyrrolidine derivatives and their use as medicaments
HUP0201900A3 (en) Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof
HUP0303524A3 (en) Novel quinuclidine derivatives, process for their preparation and medicinal compositions containing the same and their use
IL171170A (en) Maytansinoid derivatives and pharmaceutical compositions containing the same, methods of producing the same and methods of use thereof
HUP0401718A3 (en) Bicyclic oxopyridine and oxopyrimidine derivatives, their use and pharmaceutical compositions containing them
NO20014858L (en) Use of CYP2D6 inhibitors in combination therapy
IL150734A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
EE200100495A (en) Carbohydrate-substituted 1,4-benzothiazepine-1,1-dioxide derivatives, process for their preparation, use of the compounds and medicament containing them
IL152889A0 (en) Imidazopyridine and imidazopyrimidine derivatives and pharmaceutical compositions containing the same
EE05109B1 (en) Sulphonamide derivatives, their use in medicine and process for their preparation
DE60132600D1 (en) MEDICAMENTS FOR THE CHEMOTHERAPEUTIC TREATMENT OF ILLNESSES
NO20015542L (en) Process for the preparation and use of N-desmethylzopiclones
EE200100574A (en) Novel compounds, process for their preparation and use
NO20031701D0 (en) Process and intermediates in the preparation of 7-substituted antiestrogens
NO20023482D0 (en) Procedure for the treatment of substance abuse
MXPA03000644A (en) Novel indole derivatives and their use as medicaments.
IL154850A0 (en) Polysubstituted imidazopyridine derivatives and pharmaceutical compositions containing the same
EE200100711A (en) Naphthyridine derivatives, process for their preparation and pharmaceutical composition containing them

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20131025